Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Retained Earnings (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Retained Earnings for 7 consecutive years, with -$735.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Retained Earnings fell 39.73% to -$735.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$735.7 million, a 39.73% decrease, with the full-year FY2024 number at -$576.2 million, down 3601318.75% from a year prior.
  • Retained Earnings was -$735.7 million for Q3 2025 at 4D Molecular Therapeutics, down from $337000.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $337000.0 in Q2 2025 to a low of -$735.7 million in Q3 2025.
  • A 5-year average of -$289.9 million and a median of -$287.1 million in 2022 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: plummeted 3601318.75% in 2024, then skyrocketed 100.07% in 2025.
  • 4D Molecular Therapeutics' Retained Earnings stood at -$423000.0 in 2021, then tumbled by 74247.52% to -$314.5 million in 2022, then soared by 100.01% to $16000.0 in 2023, then tumbled by 3601318.75% to -$576.2 million in 2024, then dropped by 27.68% to -$735.7 million in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Retained Earnings are -$735.7 million (Q3 2025), $337000.0 (Q2 2025), and -$624.2 million (Q1 2025).